trending Market Intelligence /marketintelligence/en/news-insights/trending/rHLmbI97cAj7dHO-MlqWqA2 content esgSubNav
In This List

Ablynx establishes US subsidiary

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Ablynx establishes US subsidiary

Ablynx NV established Ablynx Inc., a subsidiary in the U.S.

Daniel Schneider will head the unit as general manager with the goal of commercializing caplacizumab in North America.

If approved by regulatory authorities, caplacizumab would be the first therapeutic specifically indicated to treat acquired thrombotic thrombocytopenic purpura.